Neoadjuvant therapies in resectable hepatocellular carcinoma : Exploring strategies to improve prognosis
Hepatocellular carcinoma (HCC), a challenging malignancy, often necessitates surgical intervention, notably liver resection. However, the high recurrence rate, reaching 70% within 5 years post-resection, significantly impacts patient outcomes. Neoadjuvant therapies aim to preoperatively address this challenge, reducing lesion size, improving surgical resection rates, deactivating potential micro-metastases, and ultimately lowering postoperative recurrence rates. This review concentrates on advances in research on and clinical use of neoadjuvant therapies for HCC, with particular attention to the use of immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4). Ongoing clinical studies exploring immunotherapy combined with a tyrosine kinase inhibitor (TKI), interventional therapy, radiotherapy, and other modalities offer promising insights into overcoming resistance to monotherapies. In summary, neoadjuvant therapies hold significant promise in terms of improving the prognosis for patients with HCC and enhancing long-term survival, particularly through innovative combination strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Bioscience trends - 18(2024), 1 vom: 19. März, Seite 21-41 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ma, Ya-Nan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical trials |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 22.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.5582/bst.2023.01436 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368729435 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368729435 | ||
| 003 | DE-627 | ||
| 005 | 20240323000841.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5582/bst.2023.01436 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM368729435 | ||
| 035 | |a (NLM)38382930 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ma, Ya-Nan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neoadjuvant therapies in resectable hepatocellular carcinoma |b Exploring strategies to improve prognosis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Hepatocellular carcinoma (HCC), a challenging malignancy, often necessitates surgical intervention, notably liver resection. However, the high recurrence rate, reaching 70% within 5 years post-resection, significantly impacts patient outcomes. Neoadjuvant therapies aim to preoperatively address this challenge, reducing lesion size, improving surgical resection rates, deactivating potential micro-metastases, and ultimately lowering postoperative recurrence rates. This review concentrates on advances in research on and clinical use of neoadjuvant therapies for HCC, with particular attention to the use of immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4). Ongoing clinical studies exploring immunotherapy combined with a tyrosine kinase inhibitor (TKI), interventional therapy, radiotherapy, and other modalities offer promising insights into overcoming resistance to monotherapies. In summary, neoadjuvant therapies hold significant promise in terms of improving the prognosis for patients with HCC and enhancing long-term survival, particularly through innovative combination strategies | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a endpoint | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a recurrence | |
| 650 | 4 | |a response | |
| 650 | 4 | |a targeted therapy | |
| 700 | 1 | |a Jiang, Xuemei |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Peipei |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioscience trends |d 2007 |g 18(2024), 1 vom: 19. März, Seite 21-41 |w (DE-627)NLM194635147 |x 1881-7823 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2024 |g number:1 |g day:19 |g month:03 |g pages:21-41 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5582/bst.2023.01436 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2024 |e 1 |b 19 |c 03 |h 21-41 | ||